

REFERENCES

1. Nation RL, Sansom LN. Bioequivalence requirements for generic products. *Pharmacol Ther* 1994; 62: 41-55.
2. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. *J Pharmacokinet Biopharm* 1987; 15: 657-80.
3. Hoffman BB, Lefkowitz RJ. Atenolol. In: Hardman JG, Molinoff PB, Ruddon RW, Gilman AG, eds. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 9th ed. USA: McGraw-Hill, 1996: 238.
4. Tenormin. Physicians' Desk Reference. 47th ed. New Jersey: Medical Economics, 1993: 1132-4.
5. Wadworth AN, Murdoch D, Brogden RN. Atenolol: A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. *Drugs* 1991; 42: 468-510.
6. Reaven GM. Role of insulin resistance in human disease. *Diabetes* 1988; 37: 1595-607.
7. van-Zyl AI, Jennings AA, Bateman ED, Opie LH. Comparison of respiratory effects of two cardio-selective beta-blocker, celiprolol and atenolol, in asthmatics with mild to moderate hypertension. *Chest* 1989; 95: 209-13.

8. Lund W, Bichan MM, Gran WM, Martin J, Stewart M, Virden JE. Atenolol. The Pharmaceutical Codex. 12th ed. London: RPSGB, 1986: 747-8.
9. Boyd RA, Chin SK, Don-Pedro O, Williams RL, Giacomini KM. The pharmacokinetics of the enantiomers of atenolol. Clin Pharmacol Ther 1989; 45: 403-10.
10. McCoy RA, Clifton GD, Clementi WA, Smith MD, Garvey TQ, Wermeling DP, Schwartz SE. Pharmacodynamics of racemic and S (-) atenolol in humans. J Clin Pharmacol 1994; 34: 816-22.
11. Stoschitzky K, Kahr S, Donnerer J, Schumacher M, Luha O, Maier R, Klein W, Lindner W. Stereoselective increase of plasma concentrations of the enantiomers of propranolol and atenolol during exercise. Clin Pharmacol Ther 1995; 57: 543-51.
12. Sullivan PA, Daly B, O'Conner R, Dineen M. Effects of atenolol on exercise-induced changes in blood pressure, plasma potassium, plasma renin activity and plasma aldosterone in essential hypertension. J Hyperten 1986; 4 (Suppl. 5): S498-500.
13. Herpin D, Cohen S, Amiel A, Boutand PH, Ciber MA. Clinical pharmacologic method for evaluation of antihypertensive and bradycardia effects of a beta-adrenoceptor blocking drug: application to atenolol. Curr Ther Res 1986; 40: 1005-16.
14. Ihlen H, Simonsen S, Welsel D. Effect of adrenaline on myocardial oxygen consumption during selective and non-selective beta-adrenoceptor blockade comparison of atenolol and pindolol. Eur J Clin Pharmacol 1984; 27: 29-34.

15. Rubin PC, Butters L, Clark D, Sumner D, Belfield A, Pledger D, Low RA, Reid JL. Obstetric aspects of the use in pregnancy-associated hypertension of the beta-adrenoceptor antagonist atenolol. *Am J Obst Gynecol* 1984; 150: 389-92.
16. Fodor JG, Chockalingam A, Drover A, Fifield F, Pauls CJ. A Comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension. *J Clin Pharmacol* 1987; 27: 892-901.
17. Greenblatt DJ, Scavone JM, Harmatz JS, Engelhardt N, Shader RI. Cognitive effects of beta-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo. *Clin Pharmacol Ther* 1993; 53: 577-84.
18. Mason WD, Winer N, Kochak G, Cohen I, Bell R. Kinetics and absolute bioavailability of atenolol. *Clin Pharmacol Ther* 1979; 25 : 408-15.
19. Mroczek WJ, Burris JF, Hogen LB, Citron DC, Barker AH, McDonald RH. Comparison of the antihypertensive effects of betaxolol to atenolol. *Am J Cardio* 1988; 61: 807-11.
20. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. *Br Med J Clin Res Ed* 1986; 293: 1145-51.
21. Sowinski KM, Forrest A, Wilton JH, Taylor AM, Wilson MF, Kazierad DJ. Effect of aging on atenolol pharmacokinetics and pharmacodynamics. *J Clin Pharmacol* 1995; 35: 807-14.

22. Bax ND, Lennard MS, Tucker GT, Wood HF, Porter NR, Malia RG, Preston FE. The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose. *Br J Clin Pharmacol* 1984; 17: 553-7.
23. Miners JO, Wing LM, Lillywhite KJ, Smith KJ. Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. *Br J Clin Pharmacol* 1984; 18: 853-60.
24. Suharmi S, Santoso B, Mulyono. Influence of atenolol on the pharmacokinetics of hydrochlorothiazide in healthy volunteers. *Eur J Pharmacol* 1990; 183: 2735-8.
25. Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B. The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients. *Br J Clin Pharmacol* 1984; 17 (Suppl. 1): S108-11.
26. Deanfield J, Wright C, Krikler S, Ribeiro P, Fox K. Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine. *N Engl J Med* 1984; 310: 951-4.
27. Leeson LJ, Benett LZ, Foster TS, Kaplan SA, Rhodes CT, Robinson JR, Shefter E, Ueda CT. Dissolution. The United States Pharmacopeia. 23th ed. Marryland: United States Pharmacopeial Convention, 1993; 23: 1791-3.
28. Hanson WA. Handbook of Dissolution Testing. Oregon: Pharmaceutical Technology Publications, 1982.

29. Phelps SJ, Alpert BS, Ward JL, Pieper JA, Lima JJ. Absorption pharmacokinetics of atenolol in patients with the Marfan Syndrome. *J Clin Pharmacol* 1995; 35: 268-74.
30. Meredith PA. Generic drugs and therapeutic equivalence. *Drug Safety* 1996; 15: 233-42.
31. Sauter R, Steinijan VW, Diletti E, Bohm A, Schulz HU. Presentation of results from bioequivalence studies. *Int J Pharmacol Ther Toxicol* 1992; 30 (Suppl. 1): S7-30.
32. Steinijans VW, Hauschke D, Jonkman JH. Controversies in bioequivalence studies. *Clin Pharmacokinet* 1992; 22: 247-53.
33. Saunders BD, Trapp RG. Estimating and comparing means. *Basic and Clinical Biostatistics*. 2nd ed. Connecticut: Paramount Publishing Business and Professional Group, 1994; 99-124.
34. Martins ML, Pierossi MA, Moraes LA, Ribeiro W, Abbib EJ, Mendes GB, Poli A, Nucci GD, Muscara MN. Comparative bioavailability of two atenolol tablet formulations in healthy male volunteers after a single dose administration. *Int J Clin Pharmacol Ther* 1997; 35: 324-8.
35. Irshad YM, Rawashdeh NM, Awwadi FF and Kato MK. Comparative pharmacokinetics of two brands of atenolol following a single oral administration. *Int J Clin Ther* 1996; 34: 457-61.